NINE MASTS CAPITAL Ltd purchased a new stake in PAREXEL International Corporation (NASDAQ:PRXL) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 143,311 shares of the medical research company’s stock, valued at approximately $12,455,000. PAREXEL International Corporation comprises about 1.5% of NINE MASTS CAPITAL Ltd’s portfolio, making the stock its 13th largest holding. NINE MASTS CAPITAL Ltd owned 0.28% of PAREXEL International Corporation at the end of the most recent quarter.

Several other large investors have also made changes to their positions in PRXL. Capstone Asset Management Co. lifted its holdings in shares of PAREXEL International Corporation by 3.8% in the 1st quarter. Capstone Asset Management Co. now owns 4,409 shares of the medical research company’s stock valued at $278,000 after acquiring an additional 160 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in shares of PAREXEL International Corporation by 1.1% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 18,537 shares of the medical research company’s stock valued at $1,170,000 after acquiring an additional 200 shares during the last quarter. First Trust Advisors LP lifted its holdings in shares of PAREXEL International Corporation by 216.7% in the 1st quarter. First Trust Advisors LP now owns 29,536 shares of the medical research company’s stock valued at $1,864,000 after acquiring an additional 20,210 shares during the last quarter. Elkfork Partners LLC lifted its holdings in shares of PAREXEL International Corporation by 7.1% in the 1st quarter. Elkfork Partners LLC now owns 3,060 shares of the medical research company’s stock valued at $193,000 after acquiring an additional 204 shares during the last quarter. Finally, Swiss National Bank lifted its holdings in shares of PAREXEL International Corporation by 1.0% in the 1st quarter. Swiss National Bank now owns 87,800 shares of the medical research company’s stock valued at $5,541,000 after acquiring an additional 900 shares during the last quarter. 87.48% of the stock is owned by hedge funds and other institutional investors.

Shares of PAREXEL International Corporation (NASDAQ:PRXL) traded up 0.02% during mid-day trading on Friday, reaching $87.95. 798,422 shares of the company’s stock traded hands. The company’s 50-day moving average price is $87.71 and its 200-day moving average price is $77.62. The stock has a market capitalization of $4.50 billion, a PE ratio of 42.69 and a beta of 0.79. PAREXEL International Corporation has a 12-month low of $51.16 and a 12-month high of $87.98.

PAREXEL International Corporation (NASDAQ:PRXL) last posted its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.94 by $0.08. PAREXEL International Corporation had a net margin of 4.49% and a return on equity of 28.98%. The business had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. During the same quarter in the prior year, the company posted $0.94 EPS. Analysts anticipate that PAREXEL International Corporation will post $3.95 earnings per share for the current year.

A number of brokerages recently commented on PRXL. Zacks Investment Research downgraded shares of PAREXEL International Corporation from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. BidaskClub downgraded shares of PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Raymond James Financial, Inc. raised shares of PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a report on Tuesday, June 20th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $88.10 price target on shares of PAREXEL International Corporation in a report on Wednesday, June 21st. Finally, Mizuho increased their price target on shares of PAREXEL International Corporation from $66.00 to $75.00 and gave the company a “buy” rating in a report on Tuesday, May 30th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company’s stock. PAREXEL International Corporation presently has a consensus rating of “Hold” and a consensus price target of $75.92.

TRADEMARK VIOLATION NOTICE: “143,311 Shares in PAREXEL International Corporation (PRXL) Purchased by NINE MASTS CAPITAL Ltd” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/16/143311-shares-in-parexel-international-corporation-prxl-purchased-by-nine-masts-capital-ltd.html.

PAREXEL International Corporation Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.